drugset / Trial / NCT03762369

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

NCT03762369

Phase 3 Unknown 384 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of CKD-351.

Timeline

Start
2018-12-07
Primary completion
2022-02-28
Completion
2022-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-351 Unknown
Subject D930 Unknown
Comparator Latanoprost Small molecule